Buffett Roasts This Healthcare-Heavy Portfolio and Its 93% Sector Bet

Well, pull up a chair and let's take a look at what you own here. Charlie Munger lived to be 99, and I'm well on my way, but I can assure you we didn't do it by investing our life savings entirely into precision medicine! We always preferred extending our longevity with Cherry Coke, See's Candies, and a good dose of compound interest.

Looking at your holdings, it seems you're betting the whole farm on humans living to be 150. I've always told folks to invest in what they understand, but unless you're the Chief of Surgery at Johns Hopkins, this level of focus is taking it to the absolute extreme. You've gathered some truly wonderful businesses here, no doubt about it, but even a wonderful business can be a terrible investment if you forget about the margin of safety. Let's open up the annual reports and see what kind of operation you're running.

When I look at your sector breakdown, my eyes nearly pop out of my head. You've parked nearly 74% of your money directly into healthcare stocks. Now, you might point to that 19.5% in the Broad Market ETF category and say, "But Warren, I'm diversified!" Don't try to pull the wool over my eyes—that ETF is XLV, which is just the S&P 500's healthcare sector. Add it all up, and over 93% of your net worth sneezes every time the FDA catches a cold.

I will give you credit where it's due: your competitive moat profile is beautiful. Over 44% of your portfolio relies on intangible assets like patents and ironclad brands (think Eli Lilly and Novo Nordisk), and another 22% benefits from high switching costs, like Intuitive Surgical's robotic platforms. Once a hospital trains its surgeons on a da Vinci machine, they aren't switching to a competitor just to save a few pennies. That’s a real, durable economic moat.

Geographically, you've mixed roughly 74% in North America with 19% in Europe, which gives you exposure to absolute powerhouses overseas. You're holding about 6.8% in cash reserves, which is acceptable. "Cash is king only when you deploy it," but idle money earns nothing. Still, 6.8% keeps just enough dry powder in your pocket for when Mr. Market gets depressed and decides to put great businesses on sale.

While you own fantastic businesses, how you've assembled them gives me heartburn. Here is where you're straying from sound investing principles:

Absolute Sector Concentration: Betting 93% on one single industry isn't value investing; it's practically running a pharmaceutical venture fund. Diversification is protection against ignorance. Regulatory "stroke-of-the-pen" risk—like Medicare changing how it negotiates drug prices—could wipe out a massive chunk of your net worth overnight.

Overpaying for Growth: Half your portfolio is parked in the "Growth" category, heavily anchored by Eli Lilly (10.2%) and Novo Nordisk (9.8%). The weight-loss drugs are a modern miracle, but Mr. Market knows that too. These stocks are priced for absolute perfection. Overpaying for growth without a margin of safety is a surefire way to lose your shirt when growth inevitably slows down.

Severe Overlap and Redundancy: You own nearly 20% in the XLV ETF, but your top individual holdings (UnitedHealth, Eli Lilly, Thermo Fisher, AbbVie) make up a massive chunk of that exact same index! You're double-dipping. You never want to pay an ETF management fee to hold the exact same stocks you already manage yourself.

Speculative Science: You've got a small allocation (1.4%) to Moderna. I stay away from businesses where the future relies on predicting clinical trial outcomes. It's speculation, pure and simple, and picking the right biotech is tougher than picking the winner of the Kentucky Derby while blindfolded.

Score: 5/10

You own some of the highest-quality businesses on earth, but you've constructed a portfolio that is dangerously lopsided and likely bought at nosebleed valuations. You're holding wonderful companies, but I suspect you paid a wonderful price for them, too.

Here is what I recommend you do tomorrow morning:

1. Pick a Lane: Decide if you want to be a stock picker or an indexer. If you want the safety of the XLV ETF, sell your redundant US healthcare stocks. If you want to hold UNH and Lilly directly, sell the ETF.

2. Diversify Outside the Ward: You need businesses that perform well when people aren't sick. Take some profits from your high-flyers and buy some consumer staples, maybe a well-run bank, or a business that moves goods from point A to point B.

3. Build the War Chest: Let your cash reserve drift up closer to 10-15%. When these high-flying growth stocks inevitably stumble on an earnings miss, you'll want the flexibility to swing at a fat pitch.

Remember what I always say: "A wonderful company at a fair price beats a fair company at a wonderful price." Make sure you know which one you're buying.